Frontiers in immunology
Treatment context is associated with thrombocytopenia report phenotypes in lung cancer: an active-comparator analysis of FAERS and JADER
Par Yang F, Jiang Q, Wei Z et 1 autres.
Contenu en anglais
Résumé
Background
Thrombocytopenia during immune checkpoint inhibitor treatment in lung cancer may be coded as immune, marrow suppression, coagulation, or non-specific. We tested whether coding-defined report phenotypes differed across co-reported treatment contexts.
Methods
We analyzed FAERS (2015Q1-2026Q2) and JADER through Japanese fiscal 2025Q4 (31 March 2026). Strict primary lung cancer reports were grouped as ICI without chemotherapy (C1), ICI plus chemotherapy (C2), or chemotherapy without ICI (C3). Firth models compared mutually exclusive immune-like and marrow-like anchors. Complementary analyses evaluated the broad cohort, treatment date compatibility, C3 small-cell influence, phenotype variants, onset windows, treatment-variable ablation in elastic-net report phenotype models, and a 120-report random stratified blinded review with independent ratings, third-person adjudication, inverse-selection weighting, and bootstrap uncertainty.